Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Turkish Adaptation of the Pediatric Voice Related Quality of Life Survey: A validity and reliability study.

Çinar R, Gökdoğan Ç, Kemaloğlu YK, Yılmaz M.

Int J Pediatr Otorhinolaryngol. 2018 Aug;111:183-186. doi: 10.1016/j.ijporl.2018.06.008. Epub 2018 Jun 8.

PMID:
29958607
2.

Synthesis of 13 C6 -labeled, dual-target inhibitor of cannabinoid-1 receptor (CB1 R) and inducible nitric oxide synthase (iNOS).

Iyer MR, Cinar R, Coffey NJ, Kunos G.

J Labelled Comp Radiopharm. 2018 May 23. doi: 10.1002/jlcr.3639. [Epub ahead of print]

PMID:
29790591
3.

Disruption of renal arginine metabolism promotes kidney injury in hepatorenal syndrome.

Varga ZV, Erdelyi K, Paloczi J, Cinar R, Zsengeller ZK, Jourdan T, Matyas C, Balazs NT, Guillot A, Xiang X, Mehal A, Hasko G, Stillman IE, Rosen S, Gao B, Kunos G, Pacher P.

Hepatology. 2018 Apr 6. doi: 10.1002/hep.29915. [Epub ahead of print]

PMID:
29631342
4.

Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach.

Valenta I, Varga ZV, Valentine H, Cinar R, Horti A, Mathews WB, Dannals RF, Steele K, Kunos G, Wahl RL, Pomper MG, Wong DF, Pacher P, Schindler TH.

JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 2):320-332. doi: 10.1016/j.jcmg.2017.11.019.

PMID:
29413441
5.

Decreasing CB1 receptor signaling in Kupffer cells improves insulin sensitivity in obese mice.

Jourdan T, Nicoloro SM, Zhou Z, Shen Y, Liu J, Coffey NJ, Cinar R, Godlewski G, Gao B, Aouadi M, Czech MP, Kunos G.

Mol Metab. 2017 Nov;6(11):1517-1528. doi: 10.1016/j.molmet.2017.08.011. Epub 2017 Sep 1.

6.

Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy.

Jourdan T, Park JK, Varga ZV, Pálóczi J, Coffey NJ, Rosenberg AZ, Godlewski G, Cinar R, Mackie K, Pacher P, Kunos G.

Diabetes Obes Metab. 2018 Mar;20(3):698-708. doi: 10.1111/dom.13150. Epub 2017 Dec 3.

PMID:
29106063
7.

Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling.

Tam J, Szanda G, Drori A, Liu Z, Cinar R, Kashiwaya Y, Reitman ML, Kunos G.

Mol Metab. 2017 Oct;6(10):1113-1125. doi: 10.1016/j.molmet.2017.06.010. Epub 2017 Jun 24.

8.

Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-Induced CKD.

Udi S, Hinden L, Earley B, Drori A, Reuveni N, Hadar R, Cinar R, Nemirovski A, Tam J.

J Am Soc Nephrol. 2017 Dec;28(12):3518-3532. doi: 10.1681/ASN.2016101085. Epub 2017 Aug 31.

PMID:
28860163
9.

Network analyses identify liver-specific targets for treating liver diseases.

Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M, Cinar R, Ståhlman M, Sikanic N, Park JK, Deshmukh S, Harzandi AM, Kuijpers T, Grøtli M, Elsässer SJ, Piening BD, Snyder M, Smith U, Nielsen J, Bäckhed F, Kunos G, Uhlen M, Boren J, Mardinoglu A.

Mol Syst Biol. 2017 Aug 21;13(8):938. doi: 10.15252/msb.20177703.

10.

Synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-(methyl-d3 )butanamide-d5 , octadeuterated JD5037.

Iyer MR, Cinar R, Coffey NJ, Chorvat RJ, Kunos G.

J Labelled Comp Radiopharm. 2017 Aug;60(10):460-465. doi: 10.1002/jlcr.3521. Epub 2017 Aug 2.

PMID:
28545167
11.

Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis.

Cinar R, Gochuico BR, Iyer MR, Jourdan T, Yokoyama T, Park JK, Coffey NJ, Pri-Chen H, Szanda G, Liu Z, Mackie K, Gahl WA, Kunos G.

JCI Insight. 2017 Apr 20;2(8). pii: 92281. doi: 10.1172/jci.insight.92281. [Epub ahead of print]

12.

β-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice.

Varga ZV, Matyas C, Erdelyi K, Cinar R, Nieri D, Chicca A, Nemeth BT, Paloczi J, Lajtos T, Corey L, Hasko G, Gao B, Kunos G, Gertsch J, Pacher P.

Br J Pharmacol. 2018 Jan;175(2):320-334. doi: 10.1111/bph.13722. Epub 2017 Feb 22.

13.

Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.

Iyer MR, Cinar R, Katz A, Gao M, Erdelyi K, Jourdan T, Coffey NJ, Pacher P, Kunos G.

J Med Chem. 2017 Feb 9;60(3):1126-1141. doi: 10.1021/acs.jmedchem.6b01504. Epub 2017 Jan 27.

PMID:
28085283
14.

Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type 2 Diabetes.

Jourdan T, Szanda G, Cinar R, Godlewski G, Holovac DJ, Park JK, Nicoloro S, Shen Y, Liu J, Rosenberg AZ, Liu Z, Czech MP, Kunos G.

Diabetes. 2017 Apr;66(4):994-1007. doi: 10.2337/db16-1199. Epub 2017 Jan 12.

15.

Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.

Knani I, Earley BJ, Udi S, Nemirovski A, Hadar R, Gammal A, Cinar R, Hirsch HJ, Pollak Y, Gross I, Eldar-Geva T, Reyes-Capo DP, Han JC, Haqq AM, Gross-Tsur V, Wevrick R, Tam J.

Mol Metab. 2016 Oct 22;5(12):1187-1199. doi: 10.1016/j.molmet.2016.10.004. eCollection 2016 Dec.

16.

Impact of Experiencing Acute Coronary Syndrome Prior to Open Heart Surgery on Psychiatric Status.

Yüksel V, Gorgulu Y, Cinar RK, Huseyin S, Sonmez MB, Canbaz S.

Braz J Cardiovasc Surg. 2016 Jul-Sep;31(4):281-286. doi: 10.5935/1678-9741.20160064.

17.

Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Cinar R, Iyer MR, Liu Z, Cao Z, Jourdan T, Erdelyi K, Godlewski G, Szanda G, Liu J, Park JK, Mukhopadhyay B, Rosenberg AZ, Liow JS, Lorenz RG, Pacher P, Innis RB, Kunos G.

JCI Insight. 2016 Jul 21;1(11). pii: e87336.

18.

Cannabinoid receptor signaling regulates liver development and metabolism.

Liu LY, Alexa K, Cortes M, Schatzman-Bone S, Kim AJ, Mukhopadhyay B, Cinar R, Kunos G, North TE, Goessling W.

Development. 2016 Feb 15;143(4):609-22. doi: 10.1242/dev.121731.

19.

Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization.

Björnson E, Mukhopadhyay B, Asplund A, Pristovsek N, Cinar R, Romeo S, Uhlen M, Kunos G, Nielsen J, Mardinoglu A.

Cell Rep. 2015 Dec 1;13(9):2014-26. doi: 10.1016/j.celrep.2015.10.045. Epub 2015 Nov 19.

20.

Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids.

Gunduz-Cinar O, Flynn S, Brockway E, Kaugars K, Baldi R, Ramikie TS, Cinar R, Kunos G, Patel S, Holmes A.

Neuropsychopharmacology. 2016 May;41(6):1598-609. doi: 10.1038/npp.2015.318. Epub 2015 Oct 30.

21.

Mice lacking GPR3 receptors display late-onset obese phenotype due to impaired thermogenic function in brown adipose tissue.

Godlewski G, Jourdan T, Szanda G, Tam J, Cinar R, Harvey-White J, Liu J, Mukhopadhyay B, Pacher P, Ming Mo F, Osei-Hyiaman D, Kunos G.

Sci Rep. 2015 Oct 12;5:14953. doi: 10.1038/srep14953.

22.

The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity.

Mukhopadhyay P, Baggelaar M, Erdelyi K, Cao Z, Cinar R, Fezza F, Ignatowska-Janlowska B, Wilkerson J, van Gils N, Hansen T, Ruben M, Soethoudt M, Heitman L, Kunos G, Maccarrone M, Lichtman A, Pacher P, Van der Stelt M.

Br J Pharmacol. 2016 Feb;173(3):446-58. doi: 10.1111/bph.13338. Epub 2016 Jan 15.

23.

Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists.

Iyer MR, Cinar R, Liu J, Godlewski G, Szanda G, Puhl H, Ikeda SR, Deschamps J, Lee YS, Steinbach PJ, Kunos G.

Mol Pharmacol. 2015 Aug;88(2):238-44. doi: 10.1124/mol.115.098541. Epub 2015 May 26.

24.

Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms.

Mukhopadhyay B, Schuebel K, Mukhopadhyay P, Cinar R, Godlewski G, Xiong K, Mackie K, Lizak M, Yuan Q, Goldman D, Kunos G.

Hepatology. 2015 May;61(5):1615-26. doi: 10.1002/hep.27686. Epub 2015 Feb 17.

25.

Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.

Jourdan T, Szanda G, Rosenberg AZ, Tam J, Earley BJ, Godlewski G, Cinar R, Liu Z, Liu J, Ju C, Pacher P, Kunos G.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5420-8. doi: 10.1073/pnas.1419901111. Epub 2014 Nov 24.

26.

Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.

Tam J, Godlewski G, Earley BJ, Zhou L, Jourdan T, Szanda G, Cinar R, Kunos G.

Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E457-68. doi: 10.1152/ajpendo.00489.2013. Epub 2013 Dec 31.

27.

Ligand-specific regulation of the endogenous mu-opioid receptor by chronic treatment with mu-opioid peptide agonists.

Murányi M, Cinar R, Kékesi O, Birkás E, Fábián G, Bozó B, Zentai A, Tóth G, Kicsi EG, Mácsai M, Dochnal R, Szabó G, Szücs M.

Biomed Res Int. 2013;2013:501086. doi: 10.1155/2013/501086. Epub 2013 Nov 24.

28.

Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase.

Liu J, Cinar R, Xiong K, Godlewski G, Jourdan T, Lin Y, Ntambi JM, Kunos G.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18832-7. doi: 10.1073/pnas.1309469110. Epub 2013 Nov 4.

29.

Chronic alcohol produces neuroadaptations to prime dorsal striatal learning.

DePoy L, Daut R, Brigman JL, MacPherson K, Crowley N, Gunduz-Cinar O, Pickens CL, Cinar R, Saksida LM, Kunos G, Lovinger DM, Bussey TJ, Camp MC, Holmes A.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14783-8. doi: 10.1073/pnas.1308198110. Epub 2013 Aug 19.

30.

Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes.

Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J, Tam J, Han T, Mukhopadhyay B, Skarulis MC, Ju C, Aouadi M, Czech MP, Kunos G.

Nat Med. 2013 Sep;19(9):1132-40. doi: 10.1038/nm.3265. Epub 2013 Aug 18.

31.

Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides.

Cinar R, Godlewski G, Liu J, Tam J, Jourdan T, Mukhopadhyay B, Harvey-White J, Kunos G.

Hepatology. 2014 Jan;59(1):143-53. doi: 10.1002/hep.26606. Epub 2013 Nov 18.

32.

Lack of regulatory changes of µ-opioid receptors by 14-methoxymetopon treatment in rat brain. Further evidence for functional selectivity.

Cinar R, Kékesi O, Birkás E, Fábián G, Schmidhammer H, Szücs M.

Curr Pharm Des. 2013;19(42):7348-54.

PMID:
23448478
33.

Domino synthesis of protochromic "ON-OFF-ON" luminescent 2-styryl quinolines.

Cinar R, Nordmann J, Dirksen E, Müller TJ.

Org Biomol Chem. 2013 Apr 28;11(16):2597-604. doi: 10.1039/c3ob27270b.

PMID:
23446649
34.

Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance.

Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, Szanda G, Mukhopadhyay B, Chedester L, Liow JS, Innis RB, Cheng K, Rice KC, Deschamps JR, Chorvat RJ, McElroy JF, Kunos G.

Cell Metab. 2012 Aug 8;16(2):167-79. doi: 10.1016/j.cmet.2012.07.002. Epub 2012 Jul 26.

35.

Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.

Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B, Godlewski G, Ramikie TS, Gorka AX, Alapafuja SO, Nikas SP, Makriyannis A, Poulton R, Patel S, Hariri AR, Caspi A, Moffitt TE, Kunos G, Holmes A.

Mol Psychiatry. 2013 Jul;18(7):813-23. doi: 10.1038/mp.2012.72. Epub 2012 Jun 12.

36.

Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy.

Rajesh M, Bátkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horváth B, Holovac E, Cinar R, Liaudet L, Mackie K, Haskó G, Pacher P.

Diabetes. 2012 Mar;61(3):716-27. doi: 10.2337/db11-0477. Epub 2012 Feb 7.

37.

Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver.

Mukhopadhyay B, Cinar R, Yin S, Liu J, Tam J, Godlewski G, Harvey-White J, Mordi I, Cravatt BF, Lotersztajn S, Gao B, Yuan Q, Schuebel K, Goldman D, Kunos G.

Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6323-8. doi: 10.1073/pnas.1017689108. Epub 2011 Mar 7.

38.

Endocannabinoids in liver disease.

Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G.

Hepatology. 2011 Jan;53(1):346-55. doi: 10.1002/hep.24077. Review.

39.

Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects.

Godlewski G, Alapafuja SO, Bátkai S, Nikas SP, Cinar R, Offertáler L, Osei-Hyiaman D, Liu J, Mukhopadhyay B, Harvey-White J, Tam J, Pacak K, Blankman JL, Cravatt BF, Makriyannis A, Kunos G.

Chem Biol. 2010 Nov 24;17(11):1256-66. doi: 10.1016/j.chembiol.2010.08.013.

41.

Reciprocal inhibition of G-protein signaling is induced by CB(1) cannabinoid and GABA(B) receptor interactions in rat hippocampal membranes.

Cinar R, Freund TF, Katona I, Mackie K, Szucs M.

Neurochem Int. 2008 Jun;52(8):1402-9. doi: 10.1016/j.neuint.2008.02.005. Epub 2008 Feb 29.

PMID:
18407377

Supplemental Content

Support Center